Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib with Amivantamab as First-line Treatment in EGFRm NSCLC
NCT05801029Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of osimertinib, amivantamab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2023; status: active, not recruiting.
02
Drugs
osimertinibamivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05801029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801029.